Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 3154 • 2016 ACR/ARHP Annual Meeting
Assessing Bone Erosions in the Metatarsophalangeal Joints of Patients with Early Rheumatoid Arthritis: a Comparison Between MRI and Ultrasound
Karen A. Beattie¹, Sydney Scheffler², George Ioannidis³, Edward Schreyer⁴, Saara Totterman⁵ and Maggie Larche¹, ¹Medicine, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴QMetrics Technologies, Rochester, NY, ⁵Radiology, VirtualScopics Inc., Rochester, NY
Background/Purpose: This cross-sectional study aimed to assess the agreement between Magnetic Resonance Imaging (MRI) and ultrasound (US) findings of bone erosions in the metatarsalphalangeal (MTP)…
Abstract Number: 492 • 2016 ACR/ARHP Annual Meeting
Calprotectin Levels Correlate with Inflammation in Early Rheumatoid Arthritis before Disease-Modifying Antirheumatic Drug Treatment and after 12 Months of Treatment
Maria K. Jonsson^1,2,3, Hilde B. Hammer⁴, Hilde H. Nordal^1,3, Anna-Birgitte Aga², Inge C Olsen², Karl Albert Brokstad³, Tore K Kvien², Bjørg-Tilde Fevang^1,5, Siri Lillegraven², Espen A. Haavardsholm² and ARCTIC study group, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Clinical Sciences, University of Bergen, Bergen, Norway, ⁴Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Calprotectin (MRP8/MRP14, S100A8/A9) is a major leukocyte protein previously shown to be associated with disease activity in patients with established rheumatoid arthritis (RA). Some…
Abstract Number: 1457 • 2016 ACR/ARHP Annual Meeting
Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Richard Bell¹, Emily Wu², Ronald Wood³, Joe Chakkalakal², Javier Rangel-Moreno⁴, Maria de la Luz Garcia-Hernandez², Christopher T. Ritchlin⁵, Edward Schwarz⁶ and Homaira Rahimi⁷, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²University of Rochaester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Orthopedeatrics, University of Rochester, Rochester, NY, ⁷Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Although exacerbated morbidity and mortality in rheumatoid arthritis (RA) is frequently seen in women, the etiology of this sexual dimorphism remains unclear. Previously, we…
Abstract Number: 3209 • 2016 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes of 5 Years Remission Steered Treatment in Early Rheumatoid and Undifferentiated Arthritis Patients
Gülsah Akdemir¹, L. Heimans², R.J. Goekoop³, Maikel van Oosterhout⁴, J.B. Harbers⁵, C. Bijkerk⁶, G.M. Steup-Beekman⁷, L.R. Lard⁸, P.B.J. de Sonnaville⁹, B.A.M. Grillet¹⁰, TWJ Huizinga¹¹ and Cornelia F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Haga Hospital, The Hague, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁶Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁷Rheumatology, Bronovo Hospital, The Hague, Netherlands, ⁸Rheumatology, MCH Antoniushove Hospital, Leidschendam, Netherlands, ⁹Rheumatology, ADRZ, Goes, Netherlands, ¹⁰Rheumatology, Zorgsaam, Terneuzen, Netherlands, ¹¹Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: To assess clinical and radiological outcomes of induction therapy followed by 5 years disease activity score (DAS)-remission steered treatment in early arthritis patients. Methods:…
Abstract Number: 501 • 2016 ACR/ARHP Annual Meeting
Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis
Dilpreet Singh¹, Jasdeep Badwal¹, Ritika Vankina¹, Santhi Gokaraju², Jennifer Friderici³, Scott Halista⁴ and Tara Lagu¹, ¹Baystate Medical Center/Tufts University School of Medicine, Springfield, MA, ²Presbyterian Hospital of Dallas, Dallas, TX, ³Baystate Medical Center, Springfield, MA, ⁴Arthritis Treatment Center, Springfield, MA
Background/Purpose: Anti-cyclic citrullinated peptide antibody (Anti-CCP) is a diagnostic tool that predicts the progression of undifferentiated polyarthritis and erosive disease in rheumatoid arthritis (RA). It…
Abstract Number: 1484 • 2016 ACR/ARHP Annual Meeting
Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Saurash Reddy, Xiaobo Meng and Carol Hitchon, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis (RA) has been established as a risk factor for cardiovascular disease (CVD), with systemic inflammation being linked with atherosclerosis. Traditional CVD risk…
Abstract Number: 3210 • 2016 ACR/ARHP Annual Meeting
10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes
Merete Lund Hetland¹, Kristian Stengaard-Pedersen², Peter Junker¹, Hanne Lindegaard¹, Torkell Ellingsen¹, Jan Pødenphant², Henrik Skjødt¹, Aage Vestergaard², Bo Jannik Ejbjerg¹, Søren Jacobsen¹, Niels Steen Krogh¹, Mikkel Ostergaard¹ and Kim Hørslev-Petersen², ¹Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Glostrup, Denmark, ²Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark
Background/Purpose: Few RCTs have investigated long-term (10+ years) outcomes of goal-directed synovitis suppression in early rheumatoid arthritis (RA). The CIMESTRA trial was a 2-year double-blinded…
Abstract Number: 508 • 2016 ACR/ARHP Annual Meeting
Before Clinically Detectable Arthritis Develops, ACPA-Positive and ACPA-Negative Arthralgia Patients Have Different Symptoms
Leonie E Burgers¹, Hanna W van Steenbergen¹, Lukas Mangnus², Tom WJ Huizinga¹ and Annette HM van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibody (ACPA)-positive and ACPA-negative rheumatoid arthritis (RA) have different genetic risk factors and underlying biological mechanisms. Therefore, we hypothesized that patients’ characteristics…
Abstract Number: 1515 • 2016 ACR/ARHP Annual Meeting
Could Increase Levels of Dickkopf-1 Protein be Considered As a Potential Biomarker for Bone Resorption in Joint and Periodontal Disease in Patients with Early Rheumatoid Arthritis?
ANA MARIA HEREDIA PALAU¹, SEBASTIAN GIRALDO QUINTERO^2,3, JULIETTE DE AVILA¹, LORENA CHILA MORENO⁴, GLORIA LAFAURIE⁵, CONSTANZA RODRIGUEZ⁴, WILSON BAUTISTA-MOLANO^5,6, PHILLIPE CHALEM CHOUEKA⁷, JUAN MANUEL BELLO GUALTEROS^3,8, RAFAEL VALLE-OÑATE^3,8 and CONSUELO ROMERO-SÁNCHEZ^4,9,10, ¹Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogota, Colombia, ²Rheumatology and Immunology Department,Hospital Militar Central, Bogota, Colombia, ³School of Medicine, Universidad Militar Nueva Granada, Bogota, Colombia, ⁴Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, BOGOTA, Colombia, ⁵Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogotá, Colombia, ⁶School of Medicine, Universidad Militar Nueva Granada, Bogotá, Colombia, ⁷Fundación Instituto de Reumatología Fernando Chalem, Bogotá, Colombia, ⁸Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia, ⁹Rheumatology and Immunology Department,Hospital Militar Central, BOGOTA, Colombia, ¹⁰School of Medicine, Universidad Militar Nueva Granada, BOGOTA, Colombia
Background/Purpose: Periodontitis and rheumatoid arthritis (RA) are chronic destructive inflammatory diseases with significant worldwide prevalence. They are characterized by inflammatory lesions adjacent to bone destruction…
Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Liam O'Neil¹, Xiaobo Meng², Irene Smolik³, Carol Hitchon² and Hani El-Gabalawy⁴, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…
Abstract Number: 567 • 2016 ACR/ARHP Annual Meeting
Understanding Contextual Factors That Influence Decisions Related to Health and Work Among People with Recently Diagnosed Rheumatoid Arthritis
Graham Macdonald¹, Catherine Backman², Anne F. Townsend³ and Linda Li⁴, ¹Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ²Occup Science & OccupTherapy, University of British Columbia, Vancouver, BC, Canada, ³Qualitative Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Department of Physical Therapy, The University of British Columbia, Vancouver, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA), early diagnosis and treatment are essential to better outcomes. Many people defer seeking help or treatment for reasons that are…
Abstract Number: 1649 • 2016 ACR/ARHP Annual Meeting
Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Eugenio Chamizo Carmona¹, Carmen Carrasco-Cubero², Juan Jose Aznar Sánchez³, Raul Veroz Gonzalez³, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez³ and Lara Chaves Chaparro¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida, Spain
Background/Purpose: The aim of early RA treatment is remission. Intensive treatment with MTX and treat-to-target approach achieve remission in 30-50% patients. Modifiable risk factors, as…
Abstract Number: 3226 • 2016 ACR/ARHP Annual Meeting
Maintenance of Clinical Remission and Radiographic Non-Progression with MTX after Completion of 1 Year Initial Treatment with Certolizumab Pegol in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Tatsuya Atsumi², Kazuhiko Yamamoto³, Tsutomu Takeuchi⁴, Hisashi Yamanaka⁵, Naoki Ishiguro⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Pauline Ralston¹¹, Désirée van der Heijde¹², Nobuyuki Miyasaka^13,14 and Takao Koike¹⁵, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³The University of Tokyo, Tokyo, Japan, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Tokyo Women's Medical University, Tokyo, Japan, ⁶Nagoya University, Nagoya, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Hays Pharma, London, United Kingdom, ¹²Leiden University Medical Center, Leiden, Netherlands, ¹³Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Sapporo Medical Center NTT EC, Sapporo, Japan
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) treatment in combination with dose-optimized MTX in Japanese MTX-naïve early RA patients (pts) with poor prognostic…
Abstract Number: 593 • 2016 ACR/ARHP Annual Meeting
Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate
Josef S. Smolen¹, Ronald F. van Vollenhoven², Benjamin A. Wolfe³, Su Chen³, Jessica L. Suboticki³ and Arthur Kavanaugh⁴, ¹Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria, ²Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA
Background/Purpose: In patients (pts) with early rheumatoid arthritis (RA), conventional synthetic DMARDs (csDMARDs), preferably methotrexate (MTX), are recommended as first line therapy.1,2 For pts who…
Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA Study Group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].